Cingulate FY2023 net loss $23.5M; cash $52k; raised $10.7M in Q1 2024

Cingulate Inc.

2024-Q1 EPS reported -$0.60

Net loss widened to $23.5M in 2023 from $17.7M; R&D expense $15.5M (+72% YoY).
Cash only $52k at year-end; $10.7M raised in Q1 2024 via ATM ($3.2M) and public offering ($7.5M).
CTx-1301 Phase 3 adult data showed trend vs placebo but not statistically significant; effect size highlighted.
FDA supports 505(b)(2) path for CTx-2103 (anxiety); IND design agreed.
Jennifer Callahan promoted to CFO; three independent directors added in Feb 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cingulate Inc. reported financial results for the twelve months ended December 31, 2023.

Period: the twelve months ended December 31, 2023
Result: reported results

Exact text from the filing

On April 1, 2024, Cingulate Inc. issued a press release announcing its financial results for the year ended December 31, 2023

View on SEC.gov

321 earnings releases filed in the last 30 days. Browse all earnings releases →

Cingulate Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-012156

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.